Ironwood Depreciation And Amortization vs Total Revenue Analysis
IRWD Stock | USD 7.82 0.26 3.22% |
Ironwood Pharmaceuticals financial indicator trend analysis is infinitely more than just investigating Ironwood Pharmaceuticals recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Ironwood Pharmaceuticals is a good investment. Please check the relationship between Ironwood Pharmaceuticals Depreciation And Amortization and its Total Revenue accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
Depreciation And Amortization vs Total Revenue
Depreciation And Amortization vs Total Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Ironwood Pharmaceuticals Depreciation And Amortization account and Total Revenue. At this time, the significance of the direction appears to have significant contrarian relationship.
The correlation between Ironwood Pharmaceuticals' Depreciation And Amortization and Total Revenue is -0.3. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Total Revenue in the same time period over historical financial statements of Ironwood Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Ironwood Pharmaceuticals' Depreciation And Amortization and Total Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Ironwood Pharmaceuticals are associated (or correlated) with its Total Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Revenue has no effect on the direction of Depreciation And Amortization i.e., Ironwood Pharmaceuticals' Depreciation And Amortization and Total Revenue go up and down completely randomly.
Correlation Coefficient | -0.3 |
Relationship Direction | Negative |
Relationship Strength | Insignificant |
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Total Revenue
Total revenue comprises all receipts Ironwood Pharmaceuticals generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.Most indicators from Ironwood Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Ironwood Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.At present, Ironwood Pharmaceuticals' Sales General And Administrative To Revenue is projected to slightly decrease based on the last few years of reporting. The current year's Enterprise Value Over EBITDA is expected to grow to 11.97, whereas Selling General Administrative is forecasted to decline to about 138.7 M.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 31.2M | 7.6M | 21.6M | 19.9M | Depreciation And Amortization | 682K | 9.5M | 1.6M | 1.5M |
Ironwood Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
Ironwood Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Ironwood Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Short Long Term Debt Total | 431.2M | 453.7M | 475.8M | 415.9M | 715.5M | 751.3M | |
Other Current Liab | 33.4M | 540K | 1.3M | 22.0M | 64.3M | 67.6M | |
Total Current Liabilities | 40.9M | 32.7M | 161.7M | 25.5M | 276.1M | 289.9M | |
Total Stockholder Equity | (93.3M) | 62.6M | 605.9M | 652.4M | (346.3M) | (329.0M) | |
Other Liab | 25.0M | 13.3M | 3.5M | 9.8M | 8.8M | 8.3M | |
Property Plant And Equipment Net | 30.2M | 25.5M | 22.9M | 20.3M | 18.2M | 19.6M | |
Current Deferred Revenue | 875K | 28.4M | 39.5M | 1.2M | 1.1M | 1.1M | |
Net Debt | 254.2M | 91.1M | (144.3M) | (240.3M) | 623.4M | 654.6M | |
Retained Earnings | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (1.7B) | (1.6B) | |
Accounts Payable | 5.5M | 661K | 935K | 483K | 7.8M | 7.4M | |
Cash | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Non Current Assets Total | 95.9M | 63.4M | 381.7M | 319.9M | 237.8M | 143.0M | |
Non Currrent Assets Other | 64.9M | 37.1M | 25.5M | 15.9M | 3.6M | 3.4M | |
Other Assets | 64.9M | 54.5M | 358.8M | 299.6M | 1.0 | 0.95 | |
Long Term Debt | 408.0M | 430.3M | 337.3M | 396.3M | 498.3M | 252.1M | |
Cash And Short Term Investments | 177.0M | 362.6M | 620.1M | 656.2M | 92.2M | 87.5M | |
Net Receivables | 117.2M | 122.4M | 114.0M | 115.5M | 129.1M | 135.6M | |
Common Stock Total Equity | 154K | 158K | 161K | 162K | 177.1K | 125.3K | |
Common Stock Shares Outstanding | 156.0M | 160.7M | 164.4M | 186.3M | 155.4M | 137.1M | |
Liabilities And Stockholders Equity | 402.7M | 559.2M | 1.1B | 1.1B | 471.1M | 499.5M | |
Non Current Liabilities Total | 455.1M | 463.9M | 359.3M | 422.6M | 541.3M | 370.6M | |
Other Current Assets | 11.9M | 9.2M | 9.8M | 7.7M | 12.0M | 17.6M | |
Other Stockholder Equity | 1.5B | 1.5B | 1.5B | 1.3B | 1.4B | 1.0B | |
Total Liab | 496.0M | 496.6M | 521.0M | 448.1M | 817.4M | 454.8M | |
Property Plant And Equipment Gross | 30.2M | 25.5M | 22.9M | 20.3M | 27.1M | 20.1M | |
Total Current Assets | 306.9M | 495.8M | 745.2M | 780.6M | 233.3M | 356.5M | |
Accumulated Other Comprehensive Income | (65.2M) | (10.1M) | (11.8M) | 0.0 | (3.0M) | (3.2M) | |
Short Term Debt | 1.1M | 3.1M | 120.0M | 3.1M | 202.7M | 212.8M | |
Common Stock | 154K | 158K | 161K | 162K | 156K | 128.1K | |
Property Plant Equipment | 12.4M | 8.9M | 22.9M | 6.3M | 5.7M | 5.4M | |
Net Tangible Assets | (72.0M) | 83.0M | 605.9M | 669.0M | 769.3M | 807.8M | |
Retained Earnings Total Equity | (1.6B) | (1.5B) | (937.6M) | (696.4M) | (626.7M) | (658.1M) | |
Long Term Debt Total | 408.0M | 430.3M | 337.3M | 396.3M | 455.7M | 311.5M | |
Capital Surpluse | 1.5B | 1.5B | 1.5B | 1.3B | 1.6B | 1.3B | |
Capital Lease Obligations | 23.2M | 23.4M | 21.6M | 19.7M | 17.7M | 9.9M | |
Deferred Long Term Liab | 97.6M | 40.1M | 24.3M | 12.1M | 13.9M | 13.2M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing. For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Complementary Tools for Ironwood Stock analysis
When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume |
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.69) | Earnings Share (6.45) | Revenue Per Share 2.848 | Quarterly Revenue Growth 0.097 | Return On Assets 0.1339 |
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.